

PATENT  
3631-0112P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: KLYSNER, Steen  
Appl. No.: NEW Group:  
Filed: October 23, 2001 Examiner:  
For: METHOD FOR DOWN-REGULATING IL5 ACTIVITY

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION CONCURRENT WITH THE  
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents  
Washington, DC 20231

October 23, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

Docket No. 3631-0112P

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.


If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. \$ 1.16 or under \$ 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH &amp; BIRCH, LLP

By

for  # 47,604  
Leonard R. Svensson, #30,330

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

LRS/lmt  
3631-0112P

Enclosures: ☒ Form PTO-1449(s)  
☐ Documents  
☐ Foreign Search Report  
☐ Fee  
☐ Other: \_\_\_\_\_

(Rev. 09/26/01)

Form PTO-1449

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY DOCKET NO.  
3631-0112P

APPLICATION NO.  
NEW

APPLICANT  
KLYSNER, Steen

FILING DATE
October 23, 2001

GROUP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
	WO 97/45448A	1997-12-04	WIPO				
	WO 95/05849A	1995-03-02	WIPO				
	WO 98/17799A	1998-04-30	WIPO				
	WO 97/00321A	1997-01-03	WIPO				
	WO 98/47923A	1998-10-29	WIPO				
	WO 95/31480A	1995-11-23	WIPO				
	WO 95/26365A	1995-10-05	WIPO				

## OTHER DOCUMENTS

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

K. TAKATSU, "Interleukin 5 and B cell differentiation," *Cytokine and Growth Factor Reviews*, Vol. 9, No. 1, pp. 25-35 (March 1998) \*

J. WELTMAN et al., "Interleukin-5: a proeosinophil cytokine mediator of inflammation in asthma and a target for antisense therapy", Allergy and Asthma Proceedings, Vol. 19, No. 5, pp. 257-261 (September 1998)

D. BROIDE et al., "Intradermal gene vaccination down-regulates both arms of the allergic response", Journal of Allergy and Clinical Immunology, Vol. 99, No. 1, part 2, p. S129 (January 1997)

EXAMINER

DATE CONSIDERED
-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.